NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
J Natl Compr Canc Netw
; 18(1): 12-22, 2020 01.
Article
in En
| MEDLINE
| ID: mdl-31910384
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematopoietic Cell Growth Factors
/
Practice Guidelines as Topic
/
Biosimilar Pharmaceuticals
/
Chemotherapy-Induced Febrile Neutropenia
/
Neoplasms
Type of study:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Natl Compr Canc Netw
Journal subject:
NEOPLASIAS
Year:
2020
Type:
Article